| Autor: |
Prisant, L. Michael, Krum, Henry, Roniker, Barbara, Krause, Scott L., Fakouhi, Kaffa, He, Weizhong |
| Zdroj: |
Journal of Clinical Pharmacology; Nov2003, Vol. 43 Issue 11, p1203-1210, 8p |
| Abstrakt: |
Since neither angiotensin-converting enzyme inhibitors (ACE-I) nor angiotensin II receptor blockers (ARB) can completely suppress aldosterone levels, there is a need for alter-native/supplementary antihypertensive medications, such as the selective aldosterone blocker eplerenone (InspraTM). This multicenter study measured the safety and efficacy of add-on eplerenone therapy to reduce blood pressure not con-trolled by ACE-I or ARB monotherapy. An ad hoc analysis evaluated whether active plasma renin or serum aldosterone levels could predict blood pressure response to eplerenone therapy. Patients (N = 341) with a diastolic blood pressure > 95 mmHg on a fixed dose of ACE-I or ARB were randomized to 8 weeks of double-blind treatment with eplerenone 50 mg qd or placebo. If blood pressure remained uncontrolled following 2, 4, or 6 weeks of treatment, the eplerenone dose was increased to 100 mg qd. In a combined cohort analysis of these patients, the placebo-adjusted change in systolic and diastolic blood pressure was -5.9/-2.4 mmHg (p < 0.001 and p = 0.006, respectively). While adding eplerenone to an ACE-I or ARB is safe and effective for blood pressure reduction, there was no baseline value or range of values of active plasma renin, serum aldosterone, or their ratio that predicted a favorable response to either of these drug combinations. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text